Navigation Links
Researchers decode biology of blood and iron disorders mapping out novel future therapies
Date:3/25/2013

NEW YORK (March 25, 2013) -- Two studies led by investigators at Weill Cornell Medical College shed light on the molecular biology of three blood disorders, leading to novel strategies to treat these diseases.

The two new studies -- one published online March 17 by Nature Medicine and the other March 25 in the online edition of the Journal of Clinical Investigation -- propose two new treatments for beta-thalassemia, a blood disorder which affects thousands of people globally every year. In addition, they suggest a new strategy to treat thousands of Caucasians of Northern European ancestry diagnosed with HFE-related hemochromatosis and a novel approach to the treatment of the rare blood disorder polycythemia vera.

These research insights were only possible because two teams that included 24 investigators at six American and European institutions decoded the body's exquisite regulation of iron, as well as its factory-like production of red blood cells.

"When you tease apart the mechanisms leading to these serious disorders, you find elegant ways to manipulate the system," says Dr. Stefano Rivella, associate professor of genetic medicine in pediatrics at Weill Cornell Medical College.

For example, Dr. Rivella says, two different gene mutations lead to different outcomes. In beta-thalassemia, patients suffer from anemia -- the lack of healthy red blood cells -- and, as a consequence, iron overload. In HFE-related hemochromatosis, patients suffer of iron overload. However, he adds, one treatment strategy that regulates the body's use of iron may work for both disorders.

Additionally, investigators found another strategy, based on manipulating red blood cell production, could also potentially treat beta-thalassemia as well as a very different disorder, polycythemia vera.

Revealing the Third Crucial Player

In the Nature Medicine study, Dr. Rivella and his colleagues tackled
'/>"/>

Contact: Lauren Woods
Law2014@med.cornell.edu
646-317-7401
Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Researchers develop a new cell and animal model of inflammatory breast cancer
3. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
4. Researchers Find Gene Mutations That May Be a Key to Autism
5. Researchers find evidence of banned antibiotics in poultry products
6. NJ stroke researchers report advances in spatial neglect research at AAN Conference
7. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
8. Researchers Map Brain Regions Linked to Intelligence
9. Researchers ID Genes That May Determine Mental Illness
10. Researchers Develop Blood Test for Depression
11. University of Cincinnati researchers win $3.7M grant from US Department of Defense
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 My Clients Plus ( http://www.MyClientsPlus.com ... The new module enables easy administration and routing ... quality care. , This application allows users such as ... attach a to-do item to a specific client, categorize ... up reoccurring reminders for follow-ups. It's designed to ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update ... FDA on Sit and Slim II . , ... or use Sit and Slim II because it contains ... as weight loss product on various websites and possibly in ... 2010 for safety reasons, can significantly increase blood pressure and/or ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 ... Assisted Living Center on Oct. 14. The $11 million ... and services, and a cooked-to-order kitchen with full-service restaurant ... Akron’s premier choice for first class Assisted Living apartments,” ... “Our residents deserve the highest quality of care and ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... California (PRWEB) October 20, 2014 Final Cut ... the release of the Citrus theme for FCPX filmmakers ... would use to describe the Citrus theme” Says Christina Austin, ... easy to look so professional.” , Citrus comes with all ... with the template are: four transitions for added style, a ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... vaccine that wards off infections , , THURSDAY, March 6 ... found on streptococcus bacteria may provide protection against strep ... by University of California, San Diego (UCSD), researchers developed ... streptococcal M protein, which plays a critical role in ...
... N.J., March 6 Smart Balance Inc. (Nasdaq:,SMBL) ... http://www.smartbalance.com on,March 14, 2008, at 9:30 a.m. ... will be issued at approximately 7 a.m. EDT ... mode. The webcast is also,available through the following ...
... those ... services - Immediate Termination of Endoscopy Center of Nevada clinics ... - Online information Available to Public, LAS VEGAS, March 6 Anthem ... Blue Shield,Foundation will make a $50,000 grant to the Nevada Health Centers to go,toward ...
... Trubion Pharmaceuticals,Inc. (Nasdaq: TRBN ), today announced that it ... ended Dec. 31, 2007, after the,close of market on March ... 13, 2008, at 2 p.m. PDT (5 p.m. EDT)., ... EDT, March,13, 2008, Participants are invited to call 877-545-1491 ...
... Calif., March 6 Longs Drug,Stores Corporation (NYSE: LDG ) today reported preliminary total retail drug,store sales ... in the comparable period,a year ago., , (Dollars in millions) ... retail drug store sales ... ...
... Inc. (Nasdaq: IDIX ), a biopharmaceutical company ... the treatment of human viral,and other infectious diseases, ... and year ended December 31, 2007. At December ... totaled,$112.0 million., Significant company ...
Cached Medicine News:Health News:Scientists Engineer Protein That Could Battle Strep 2Health News:Smart Balance to Host Webcast/Conference Call on 2007 Fourth-Quarter and Full-Year Results 2Health News:Anthem Blue Cross and Blue Shield Acts to Support Las Vegans Impacted by Endoscopy Center Practices 2Health News:Anthem Blue Cross and Blue Shield Acts to Support Las Vegans Impacted by Endoscopy Center Practices 3Health News:Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call 2Health News:Longs Reports Preliminary February Retail Drug Store Sales 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 8
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014   BioNano ... the Irys system: the ability to collect human data at ... on a single chip.  This new capability was established and ... for the Irys TM System and will ... next two months. BioNano will be showcasing this advancement at ...
(Date:10/20/2014)... , Oct. 20, 2014 Pharmaceutic Labs announces ... in Albany, NY for admixing, ... company meets and/or exceeds the FDA standards for safety ... CFR Part 211. The 10,000 square ... levels of quality assurance and quality control. The company ...
(Date:10/19/2014)... , October 20, 2014 Shire plc ... Bowling , Interim Chief Financial Officer (CFO), has notified the Board ... role to pursue a new career opportunity as CFO of Severn ... 2015 and the company will commence a search for a new ... "James has helped build and lead a high-quality finance ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... Ill., Nov. 8, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... 8, 2010 Reportlinker.com announces that a ... its catalogue: The Future ... leading companies, and opportunities for target expansion ... G-Protein-coupled receptors (GPCRs) constitute the largest ...
Cached Medicine Technology:Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 2Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 3Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 4Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 5Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 6Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 7Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 8The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 2The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 3The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 4The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 5